# Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

> **NCT01739127** · — · COMPLETED · sponsor: **University of British Columbia** · enrollment: 83 (actual)

## Conditions studied

- Psychotic Disorders
- Bipolar Disorder
- Metabolic Syndrome X

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Risperidone/Quetiapine

## Key facts

- **NCT ID:** NCT01739127
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2016-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739127, "Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01739127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*